Immunotherapy in colorectal cancer: an unmet need deserving of change
The efficacy of immunotherapy in colorectal cancer is currently restricted to patients with metastatic colorectal cancer presenting deficient mismatch repair (dMMR) or microsatellite instability (MSI). So far, neither immunotherapy agents as monotherapy nor immunotherapybased combinations have shown benefit for metastatic colorectal cancer with proficient mismatch repair (pMMR) or ...